MedPath
FDA Approval

Carboprost Tromethamine

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
Effective Date
November 1, 2023
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Carboprost tromethamine(250 ug in 1 mL)

Registrants1

Companies and organizations registered with the FDA for this drug approval, including their contact information and regulatory details.

Steriscience Pte. Limited

659844097

Manufacturing Establishments1

FDA-registered manufacturing facilities and establishments involved in the production, packaging, or distribution of this drug product.

Stelis Biopharma Limited

Xellia Pharmaceuticals USA LLC

Steriscience Pte. Limited

867530307

Products1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Carboprost Tromethamine

Product Details

NDC Product Code
70594-112
Application Number
ANDA216897
Marketing Category
ANDA (C73584)
Route of Administration
INTRAMUSCULAR
Effective Date
November 1, 2023
Code: U4526F86FJClass: ACTIMQuantity: 250 ug in 1 mL
© Copyright 2025. All Rights Reserved by MedPath